Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
13-Apr-2026 | 980 | 1,043.8 | 975.1 | 1,040.15 | 2,664 | 7,45,45,400.55 | 38,467 |
15-Apr-2026 | 1,078 | 1,088.8 | 1,046.05 | 1,069.05 | 4,243 | 8,47,58,572.85 | 51,104 |
16-Apr-2026 | 1,072 | 1,081.25 | 1,026.9 | 1,039.55 | 3,339 | 5,86,45,390.9 | 34,541 |
17-Apr-2026 | 1,055.55 | 1,083 | 1,033.9 | 1,039.85 | 1,735 | 2,90,98,369.35 | 18,220 |
20-Apr-2026 | 1,030 | 1,078 | 1,011.35 | 1,022.85 | 2,774 | 5,79,86,067.5 | 26,354 |
21-Apr-2026 | 1,022 | 1,069 | 1,020 | 1,024 | 1,944 | 3,28,25,384.95 | 21,308 |
22-Apr-2026 | 1,038 | 1,059 | 991 | 1,052.15 | 2,755 | 6,59,65,438.2 | 36,357 |
23-Apr-2026 | 1,057 | 1,057 | 999.55 | 999.55 | 1,635 | 8,21,58,823.95 | 51,453 |
24-Apr-2026 | 967 | 984.75 | 949.6 | 949.6 | 1,133 | 7,96,84,978.65 | 66,397 |
27-Apr-2026 | 908.4 | 982.15 | 902.15 | 937.3 | 4,472 | 15,72,46,045.55 | 1,22,170 |
28-Apr-2026 | 959.95 | 959.95 | 905.2 | 912.2 | 2,399 | 4,08,72,978.5 | 27,194 |
29-Apr-2026 | 920 | 949.95 | 909.95 | 933.3 | 1,829 | 5,10,20,597.95 | 38,620 |
30-Apr-2026 | 933.45 | 975 | 923.45 | 967.4 | 3,680 | 3,84,48,544.85 | 25,892 |
04-May-2026 | 998.9 | 998.9 | 958 | 984 | 2,805 | 5,85,40,386 | 38,850 |
05-May-2026 | 980.05 | 984 | 935 | 949.9 | 1,459 | 3,11,17,695.9 | 21,667 |
06-May-2026 | 948 | 953.7 | 902.45 | 929.85 | 2,679 | 5,15,66,492.2 | 26,965 |
07-May-2026 | 929.85 | 976.3 | 924.2 | 967.8 | 2,041 | 3,70,96,709 | 24,746 |
08-May-2026 | 973 | 1,016.15 | 972.7 | 1,006.75 | 3,085 | 8,10,40,742.8 | 51,870 |
11-May-2026 | 1,006.75 | 1,027.95 | 965 | 973.05 | 2,367 | 3,79,35,455.85 | 21,877 |
12-May-2026 | 951 | 980.9 | 925.1 | 931.7 | 1,927 | 2,81,00,576.55 | 19,947 |
The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner.
The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
